Mimedx (MDXG) Gross Margin (2011 - 2026)

Mimedx (MDXG) posted Gross Margin of 68.96% for Q2 2026, down 2.27% sequentially from 70.56% in Q1 2026, and down 1210.0% YoY from 6.21% in Q2 2025.

Mimedx (MDXG) Gross Margin (2011 - 2026) Analysis & Trends

Mimedx has reported Gross Margin for 16 years, with the latest figure at 68.96% in Q2 2026.

Quarterly Gross Margin fell 1210.0% year-over-year to 68.96% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 78.85% (down 260.0% YoY) and the FY2025 annual result came in at 82.56%, down 22.0% from the prior year.
Gross Margin fell to 68.96% in Q2 2026 per MDXG's latest filing, from 70.56% in the prior quarter.
Over five years, Gross Margin peaked at 84.67% in Q1 2024 and troughed at 68.96% in Q2 2026.
A 5-year average of 81.14% and a median of 82.16% in 2022 frame the typical range for Gross Margin.
The sharpest annual moves came in 2023 and 2026: Gross Margin soared 338 bps in 2023, then slumped 1210 bps in 2026.
Over 5 years, Gross Margin stood at 80.68% in 2022, then rose by 4 bps to 84.06% in 2023, then dropped by 3 bps to 81.8% in 2024, then rose by 3 bps to 83.86% in 2025, then retreated by 18 bps to 68.96% in 2026.
According to Business Quant data, Gross Margin over the past three periods registered 68.96%, 70.56%, and 83.86% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	91.59%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	90.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	89.76%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	60,631,834.75%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	76.90%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	84.20%
10	Mimedx	622.24 Mn	486.40 Mn	44.38 Mn	68.96%

Download Data